Emerging research indicates that SGLT2 inhibitors may also decelerate NAFLD progression, as evidenced by improvements in transient elastography and reductions in liver enzyme levels [116]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.